Gene modification strategies using AO-mediated exon skipping and CRISPR/Cas9 as potential therapies for Duchenne muscular dystrophy patients. (2020)
Attributed to:
FUTURE TARGETED HEALTHCARE MANUFACTURING HUB
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1049/enb.2020.0017
PubMed Identifier: 36968157
Publication URI: http://europepmc.org/abstract/MED/36968157
Type: Journal Article/Review
Volume: 4
Parent Publication: Engineering biology
Issue: 3
ISSN: 2398-6182